Clinical trials: Attention Deficit Disorders With Hyperactivity
ADHD
Lifestyle Enhancement for ADHD Program
The purpose of this study is to investigate if physical activity (PA) can increase in children with Attention Deficit/Hyperactivity Disorder (ADHD) using a modified behavioral management training (BMT) program.
- Trial name
- LEAP (NCT03690674)
- Testing
- Lifestyle Enhancement for ADHD Program
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Traumatic Brain Injury, Attention Deficit Disorder
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can help with attention deficits due to traumatic brain injury (TBI).
- Trial name
- NCT01000064
- Testing
- Vyvanse, fMRI
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
- Trial name
- NCT03231800
- Testing
- dasotraline
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Purpose of the study: evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.
- Trial name
- NCT04569357
- Testing
- Prospekta
- Where
- 31 sites in Russia
- Volunteers
- 363 people
- Sponsor
- Materia Medica Holding
ADHD
Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
This will be an open label study using daily does of up to 126mg/day of Concerta in the treatment of children and adolescents, ages 12-17, who meet DSM-IV criteria for ADHD.
- Trial name
- NCT00593112
- Testing
- OROS methylphenidate, No intervention
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder, Cannabis Abuse
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
- Trial name
- PEACE (NCT00687609)
- Testing
- Atomoxetine
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To assess the efficacy and safety of efficacy of MTS compared to placebo
- Trial name
- NCT00499863
- Testing
- methylphenidate transdermal system
- Where
- 32 sites in United States
- Volunteers
- 217 people
- Sponsor
- Noven Therapeutics
ADHD, Attention Deficit Disorder
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
- Trial name
- NCT05200936
- Testing
- MM120
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 53 people
- Sponsor
- Definium Therapeutics US, Inc.
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
A three-arm, randomized, double-blind, placebo-controlled, Phase 4, multicenter study to compare the efficacy and safety of atomoxetine versus placebo in children and adolescents aged 6 through 17 years with…
- Trial name
- NCT00406354
- Testing
- Atomoxetine
- Where
- 6 sites in Germany
- Volunteers
- 181 people
- Sponsor
- Eli Lilly and Company
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
ADHD, Predominantly Hyperactive - Impulsive, Behavior Problems, Child
Triple P forADHD Children's Mothers, Education of Behavioral Problems, and Change in Mothers' Attitude
The goal of this clinical trial is to investigate whether the Triple P program will reduce behavioral problems for ADHD children, improve mothers' sense of competency, and improve their attitudes The main questions it aims to…
- Conditions
- ADHD, Predominantly Hyperactive - Impulsive, Behavior Problems, Child, ADHD - Attention Deficit Disorder With Hyperactivity, Healthy Adult Females
- Trial name
- (ADHD) (NCT07069621)
- Testing
- Triple p level parenting program
- Where
- Palestinian Territories
- Volunteers
- 67 people
- Sponsor
- Palestine Polytechnic University
Attention Deficit Hyperactivity Disorder
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Although Attention Deficit/ Hyperactive Disorder (ADHD) is a common comorbidity in individuals diagnosed with Substance Use Disorder (SUD), little data currently exists on the utility of screening tools in large samples of adult…
- Trial name
- NCT00953862
- Testing
- Atomoxetine
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Attention Deficit Hyperactivity Disorder, Adherence, Medication
Web Based Tools to Improve Medication Continuity in Adolescents With ADHD
Medication is an efficacious treatment strategy for adolescents with attention-deficit/hyperactivity disorder (ADHD), however use significantly declines during adolescence when the consequences of ADHD are most severe (e.g.
- Trial name
- NCT04386096
- Testing
- Mehealth for ADHD software with medication continuity tools, Mehealth for ADHD software with no medication continuity tools
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.
ADHD
CTx-1301 Comparative Bioavailability Study
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301.
- Trial name
- NCT04138498
- Testing
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
ADHD
Evaluation of an Intervention for Improving Community-based Pediatric Attention-Deficit Hyperactivity Disorder (ADHD) Care
ADHD is the most prevalent mental health disorder of childhood. The majority of children with ADHD receive their care in primary care settings.
- Trial name
- NCT01143701
- Testing
- ADHD Collaborative
- Where
- United States
- Volunteers
- 577 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Autism, Autism Spectrum Disorder (ASD)
ScanBrit Dietary Intervention in Autism
A growing body of research indicates that dietary intervention excluding foods containing the proteins, gluten and casein, from the diet of children diagnosed with an autism spectrum disorder (ASD) may have a positive effect on…
- Trial name
- ScanBrit (NCT00614198)
- Testing
- Gluten- and casein-free diet
- Volunteers
- 72 people
- Sponsor
- Center for Autisme, Denmark
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD
This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD.
- Trial name
- NCT00506285
- Testing
- Methylphenidate Transdermal System (MTS)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of Utah